

WEST Search History

FILE COPY
09/847,355

DATE: Friday, August 16, 2002

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ</i>			
L3	L2 same virus	2	L3
L2	L1 same purging	43	L2
L1	neoplastic cells	4142	L1

END OF SEARCH HISTORY

WEST Search HistoryFILE COPY
09/847,355

DATE: Friday, August 16, 2002

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ</i>			
L12	L9 and organ	25	L12
L11	L9 and tissue	43	L11
L10	L9 and hematopoietic	20	L10
L9	L3 same (treatment)	57	L9
L8	L3 and (organ)	103	L8
L7	L3 and (tissue)	211	L7
L6	L3 same (organ)	10	L6
L5	L3 same (tissue)	63	L5
L4	L3 same (hematopoietic)	11	L4
L3	L1 same (virus)	291	L3
L2	L1 same (mixed cellular composition)	3	L2
L1	neoplastic cell	4142	L1

END OF SEARCH HISTORY

FILE COPY
09/847,355

DIALOG

Set	Items	Description
S1	2526	NEOPLASTIC CELL?
S2	10	S1 AND PURGING
S3	0	S2 AND VIRUS
S4	10	RD S2 (unique items)
S5	10	S2 NOT PY>2000
S6	454	S1 AND VIRUS
S7	84	S1 AND HEMATOPOIETIC
S8	7	S6 AND HEMATOPOIETIC
S9	7	RD S8 (unique items)
S10	6	S9 NOT PY>2000

? t s5/medium/1-10

>>>"MEDIUM" is not a valid format name in file(s): 41

5/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2002 BIOSIS. All rts. reserv.

13086694 BIOSIS NO.: 200100293843

Real time PCR for molecular monitoring of minimal residual disease in multiple myeloma patients undergoing autologous transplantation with in vitro purged hematopoietic stem cells.

AUTHOR: Barbui A M(a); Dotti G(a); Barbui T(a); Rambaldi A(a)

AUTHOR ADDRESS: (a)Divisione di Ematologia, Ospedali Riuniti, Bergamo** Italy

JOURNAL: Blood 96 (11 Part 1):p184a November 16, 2000

MEDIUM: print

CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of Hematology San Francisco, California, USA December 01-05, 2000

SPONSOR: American Society of Hematology

ISSN: 0006-4971

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

5/3/2 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2002 BIOSIS. All rts. reserv.

10884795 BIOSIS NO.: 199799505940

A new 'two step' procedure for 4.5 log depletion of T and B cells in allogeneic transplantation and of neoplastic cells in autologous transplantation.

AUTHOR: Bertolini F(a); Thomas T; Battaglia M; Gibelli N; Pedrazzoli P; Robustelli Della Cuna G

AUTHOR ADDRESS: (a)Div. Med. Oncol., IRCCS Maugeri Found., Pavia Med. Cent., viale Boezio 26, 27100 Pavia**Italy

JOURNAL: Bone Marrow Transplantation 19 (6):p615-619 1997

ISSN: 0268-3369

RECORD TYPE: Abstract

LANGUAGE: English

5/3/3 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2002 BIOSIS. All rts. reserv.

10047551 BIOSIS NO.: 199598502469

Amifostine improves the antileukemic therapeutic index of mafosfamide:

Implications for bone marrow **purging**.

AUTHOR: Douay Luc(a); Hu Chen; Giarratana Marie-Catherine; Bouchet Sandrine; Conlon John; Capizzi Robert L; Gorin Norbert-Claude

AUTHOR ADDRESS: (a)Lab. Hematologie, Hoptial de'enfants Armand Trousseau, 26 Ave. du Docteur Arnold Netter, 75571 P**France

JOURNAL: Blood 86 (7):p2849-2855 1995

ISSN: 0006-4971

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

5/3/4 (Item 4 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2002 BIOSIS. All rts. reserv.

09263389 BIOSIS NO.: 199497271759

Positive selection of hematopoietic CD34+ stem cells provides 'indirect purging' of CD34- lymphoid cells and the purging efficiency is increased by anti-CD2 and anti-CD30 immunotoxins.

AUTHOR: Lemoli R M(a); Tazzari P L; Fortuna A; Bolognesi A; Gulati S C; Stirpe F; Tura S

AUTHOR ADDRESS: (a)Inst. Ematol. Seragnoli, Univ. Bologna, Via Massarenti 9, 40138 Bologna**Italy

JOURNAL: Bone Marrow Transplantation 13 (4):p465-471 1994

ISSN: 0268-3369

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

5/3/5 (Item 1 from file: 266)

DIALOG(R)File 266:FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00326488

IDENTIFYING NO.: 5R01GM38645-12 AGENCY CODE: CRISP

CLASSIFIERS FOR HIGH SPEED, HIGH-RESOLUTION CELL SORTING

PRINCIPAL INVESTIGATOR: LEARY, JAMES F

ADDRESS: UNIV OF TEXAS MEDICAL BRANCH 301 UNIVERSITY BLVD GALVESTON, TX 77555-0835

PERFORMING ORG.: UNIVERSITY OF TEXAS MEDICAL BR GALVESTON, GALVESTON, TEXAS

SPONSORING ORG.: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

FY : 2001

5/3/6 (Item 2 from file: 266)

DIALOG(R)File 266:FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00307700

IDENTIFYING NO.: 2R44CA84924-02 AGENCY CODE: CRISP

TUMOR CELL PURGING USING FLUORESCENT ANTIBODIES

PRINCIPAL INVESTIGATOR: HANANIA, ELIE G

ADDRESS: ONCOSIS 6199 CORNERSTONE CT SUITE 111 SAN DIEGO, CA 92121-4740

PERFORMING ORG.: ONCOSIS, INC., SAN DIEGO, CALIFORNIA

SPONSORING ORG.: NATIONAL CANCER INSTITUTE

FY : 2001

5/3/7 (Item 3 from file: 266)

DIALOG(R)File 266:FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00306200

IDENTIFYING NO.: 5R01CA79763-03 AGENCY CODE: CRISP

SELECTIVE THERAPY OF NEUROBLASTOMA

PRINCIPAL INVESTIGATOR: POTTER, PHILIP M

ADDRESS: ST JUDE CHILDRENS RES HOSP 332 NORTH LAUDERDALE MEMPHIS, TN 38105

PERFORMING ORG.: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, MEMPHIS, TENNESSEE

SPONSORING ORG.: NATIONAL CANCER INSTITUTE

FY : 2001

5/3/8 (Item 4 from file: 266)

DIALOG(R)File 266:FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00305960

IDENTIFYING NO.: 5R21CA78693-02 AGENCY CODE: CRISP
PROGENITOR COLONY RT-PCR ANALYSIS IN CML TREATMENT
PRINCIPAL INVESTIGATOR: EHRLICH, MELANIE
ADDRESS: TULANE UNIV MEDICAL CENTER 1430 TULANE AVE NEW ORLEANS, LA 70112
PERFORMING ORG.: TULANE UNIVERSITY OF LOUISIANA, NEW ORLEANS, LOUISIANA
SPONSORING ORG.: NATIONAL CANCER INSTITUTE
FY : 2001

5/3/9 (Item 5 from file: 266)

DIALOG(R)File 266:FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00304986

IDENTIFYING NO.: 5R29CA75113-06 AGENCY CODE: CRISP
REGULATED TOXIN GENE THERAPY FOR RHABDOMYOSARCOMA
PRINCIPAL INVESTIGATOR: CRIPE, TIMOTHY P
ADDRESS: CHILDREN'S HOSPITAL MEDICAL CT 3333 BURNET AVENUE CINCINNATI, OH 45229
PERFORMING ORG.: CHILDREN'S HOSPITAL MED CTR (CINCINNATI), CINCINNATI, OHIO
SPONSORING ORG.: NATIONAL CANCER INSTITUTE
FY : 2001

5/3/10 (Item 6 from file: 266)

DIALOG(R)File 266:FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00304736

IDENTIFYING NO.: 5K08CA73825-04 AGENCY CODE: CRISP
~~CLONOTYPIC PCR FOR MINIMAL RESIDUAL DISEASE IN LYMPHOMA~~
PRINCIPAL INVESTIGATOR: NOY, ARIELA
ADDRESS: MEM SLOAN KETTERING CANCER CTR 1275 YORK AVE NEW YORK, NY 10021
PERFORMING ORG.: SLOAN-KETTERING INSTITUTE FOR CANCER RES, NEW YORK, NEW YORK
SPONSORING ORG.: NATIONAL CANCER INSTITUTE
FY : 2001

? t s5/k/1-10

>>>KWIC option is not available in file(s): 41, 77, 399

5/K/1 (Item 1 from file: 5)

DIALOG(R)File 5:(c) 2002 BIOSIS. All rts. reserv.

...ABSTRACT: and no transplant related mortality has been seen so far.
Before and after in vitro **purging**, minimal residual disease (MRD)
was evaluated by Real Time (RT) quantitative and semi quantitative PCR...

...cells (range 103-105) and confirmed the significant tumor cells
debulking obtained by in vitro **purging**. A prospective in vivo
evaluation of MRD is currently undergoing by this Real-time PCR...

DESCRIPTORS:

...ORGANISMS: PARTS ETC: **neoplastic cell**
CHEMICALS & BIOCHEMICALS: ...**neoplastic cell contamination**
...METHODS & EQUIPMENT: **contaminant purging, equipment...**

...contaminant **purging, equipment...**

...contaminant **purging, equipment...**

5/K/2 (Item 2 from file: 5)
DIALOG(R)File 5:(c) 2002 BIOSIS. All rts. reserv.

ABSTRACT: To evaluate a new 'two step' method for **purging** T, B and neoplastic cells from hematopoietic progenitor cells (PC), PCs were collected by apheresis...

...7%, T and B cell removal was 4.7 +- 0.4 log and neoplastic cell **purging** was 4.4 +- 0.3 log, i.e. significantly superior to methods described in the...

MISCELLANEOUS TERMS: ...**NEOPLASTIC CELLS**...

...**PURGING METHOD**

5/K/3 (Item 3 from file: 5)
DIALOG(R)File 5:(c) 2002 BIOSIS. All rts. reserv.

Amifostine improves the antileukemic therapeutic index of mafosfamide: Implications for bone marrow **purging**.

...ABSTRACT: cells by protecting normal tissues. One potential application of this protector is during bone marrow **purging** to selectively remove contaminating cancer cells. This study took normal or leukemic marrow from human...

...cells allows a higher LD-95 concentration of mafosfamide to be used in ex vivo **purging**. In contrast, amifostine pretreatment increased the cytotoxicity of mafosfamide on the fresh human leukemia progenitor...

MISCELLANEOUS TERMS: ...**NEOPLASTIC CELL**

5/K/4 (Item 4 from file: 5)
DIALOG(R)File 5:(c) 2002 BIOSIS. All rts. reserv.

Positive selection of hematopoietic CD34+ stem cells provides 'indirect **purging**' of CD34- lymphoid cells and the **purging** efficiency is increased by anti-CD2 and anti-CD30 immunotoxins.

...ABSTRACT: tumor cells from the enriched CD34+ cell fraction was demonstrated. To increase the neoplastic cell **purging**, several immunotoxins (IT) containing the ribosome-inactivating protein (RIP) saporin and directed toward the lymphoid...

...CD34+ cells purification and IT treatment resulted in 5 or more log of tumor cell **purging** with no additional loss of BM progenitor cells.

MISCELLANEOUS TERMS: ...**NEOPLASTIC CELL PURGING**;

5/K/5 (Item 1 from file: 266)
DIALOG(R)File 266:Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

...SUMMARY: biology. For clinical research, applications such as stem cell isolation (with perhaps simultaneous tumor **purging** and gene therapy) are on the horizon. For commercial applications, high-speed sorting of bacterial...

...DESCRIPTORS: evaluation; computer program /software; human subject; classification; data collection methodology /evaluation; statistics /biometry; breast neoplasm; **neoplastic cell**; metastasis; cell population study; digital imaging; cell line; clinical research; stem cell

5/K/6 (Item 2 from file: 266)

DIALOG(R)File 266:Comp & dist by NTIS, Intl Copyright All Rights Res. All
rts. reserv.

TUMOR CELL PURGING USING FLUORESCENT ANTIBODIES

...SUMMARY: Therefore, technology that reliably eliminates detectable tumor cells, while leaving HSCs undamaged, is needed. Several **purging** methods have been developed, but they are known to be inadequate. An innovative approach integrating...

... and killing every detectable tumor cell, provides a unique opportunity to evaluate the efficacy of **purging** in a setting where information on total tumor burden within the transplant is generated, down...

... the level of one detectable cell within the transplant. Although this proposal describes a tumor **purging** application, there are numerous other research and clinical applications that will be enabled once the...

...DESCRIPTORS: cytometry; computer program /software; fluorescent dye /probe; human tissue; monoclonal antibody; tumor antigen; breast neoplasm; **neoplastic cell**; image processing; laser; autologous transplantation; technology /technique development; nonHodgkin's lymphoma; bone marrow **purging**; charge coupled device camera; bioimaging /biomedical imaging ; stem cell transplantation

5/K/7 (Item 3 from file: 266)

DIALOG(R)File 266:Comp & dist by NTIS, Intl Copyright All Rights Res. All
rts. reserv.

...SUMMARY: of this approach as a potential treatment for minimum residual disease and in the **purging** of marrow for autologous transplant. The goals of this proposal are to determine: 1) the...

...DESCRIPTORS: prodrug; enzyme inhibitor; gene expression; genetic promoter element; genetic transcription; transcription factor; human tissue ; neuroblastoma; **neoplastic cell**; neoplasm /cancer chemotherapy; DNA topoisomerase; complementary DNA; protein structure function; cytotoxicity; enzyme activity; CD34...

5/K/8 (Item 4 from file: 266)

DIALOG(R)File 266:Comp & dist by NTIS, Intl Copyright All Rights Res. All
rts. reserv.

...SUMMARY: conducted of CML patients undergoing a new treatment protocol involving an induction regimen, in vivo **purging**, stem cell mobilization into the peripheral blood, leukapheresis, autologous peripheral blood stem cell transplantation and...

... contamination of peripheral blood samples and bone marrow samples with leukemic cells after in vivo **purging**. Also, the proposed analysis will provide needed preliminary data for a larger study to test...

...DESCRIPTORS: myeloid stem cell; leukapheresis; polymerase chain reaction; prognosis; cytogenetics; human subject; oncoprotein; chronic myelogenous leukemia; **neoplastic cell**; neoplasm /cancer relapse /recurrence; neoplasm /cancer chemotherapy; RNA; human therapy evaluation; tissue /cell culture...

5/K/9 (Item 5 from file: 266)

DIALOG(R)File 266:Comp & dist by NTIS, Intl Copyright All Rights Res. All
rts. reserv.

...SUMMARY: eliminating tumor cells from a mixed cell population as a model for autologous bone marrow **purging** will also be tested. Conditions for in vivo gene transfer to human xenografted tumor cells...

...DESCRIPTORS: immunoconjugate; bacterial toxin; disease /disorder model
; neoplasm /cancer genetics; rhabdomyosarcoma; lung neoplasm; neoplasm
/cancer transplantation; **neoplastic cell**; cell population study; DNA
binding protein; lung alveolus; tissue /cell culture; autologous
transplantation; Adenoviridae; bone marrow **purging**; SCID mouse

5/K/10 (Item 6 from file: 266)
DIALOG(R) File 266:Comp & dist by NTIS, Intl Copyright All Rights Res. All
rts. reserv.

...DESCRIPTORS: subject; neoplasm /cancer classification /staging;
neoplasm /cancer diagnosis; neoplasm /cancer genetics; neoplasm /cancer
immunology; lymphoma; **neoplastic cell**; autologous transplantation;
human genetic material tag; bone marrow **purging**; chronic lymphocytic
leukemia; clinical research; minimal residual disease; outcomes research
?

? t s10/medium/1-6

>>>"MEDIUM" is not a valid format name in file(s): 41

10/3/1 (Item 1 from file: 94)

DIALOG(R)File 94:JICST-EPlus

(c)2002 Japan Science and Tech Corp(JST). All rts. reserv.

02676587 JICST ACCESSION NUMBER: 96A0128640 FILE SEGMENT: JICST-E
c-Cbl Is Inducibly Tyrosine-phosphorylated by Epidermal Growth Factor
Stimulation in Fibroblasts, and Constitutively Tyrosine-phosphorylated
and Associated with v-Src in v-src-transformed Fibroblasts.

ODAI H (1); SASAKI K (1); HANAZONO Y (1); UENO H (1); TANAKA T (1);

MIYAGAWA K (1); MITANI K (1); YAZAKI Y (1); HIRAI H (1)

(1) Univ. Tokyo, Tokyo

Jpn J Cancer Res, 1995, VOL.86,NO.12, PAGE.1119-1126, FIG.5, REF.40

JOURNAL NUMBER: F0633ABW ISSN NO: 0910-5050

UNIVERSAL DECIMAL CLASSIFICATION: 616-006.2

LANGUAGE: English COUNTRY OF PUBLICATION: Japan

DOCUMENT TYPE: Journal

ARTICLE TYPE: Short Communication

MEDIA TYPE: Printed Publication

10/3/2 (Item 2 from file: 94)

DIALOG(R)File 94:JICST-EPlus

(c)2002 Japan Science and Tech Corp(JST). All rts. reserv.

01871392 JICST ACCESSION NUMBER: 93A0662171 FILE SEGMENT: JICST-E
Introduction of Foreign Gene into Reaggregate-Cultured Hepatocytes, and
Their Transplantation.

OGAWA KATSUHIRO (1); NISHIKAWA YUJI (1); INAGAKI MITSUHIRO (1); MITO MICHIO
(1)

(1) Asahikawa Medical College

Gekkan Soshiki Baiyo(Tissue Culture), 1993, VOL.19,NO.9, PAGE.336-339,

FIG.3, TBL.1, REF.10

JOURNAL NUMBER: F0781BAM ISSN NO: 0386-1791

UNIVERSAL DECIMAL CLASSIFICATION: 57.086 616/618-76/78

LANGUAGE: Japanese COUNTRY OF PUBLICATION: Japan

DOCUMENT TYPE: Journal

ARTICLE TYPE: Commentary

MEDIA TYPE: Printed Publication

10/3/3 (Item 3 from file: 94)

DIALOG(R)File 94:JICST-EPlus

(c)2002 Japan Science and Tech Corp(JST). All rts. reserv.

01629300 JICST ACCESSION NUMBER: 92A0600952 FILE SEGMENT: JICST-E
Transcription Factors in Hemopoietic Cell Differentiation.

NAKANO TOORU (1)

(1) Kyoto Univ., Faculty of Medicine

Saibo Kogaku(Cell Technology), 1992, VOL.11,NO.7, PAGE.474-480, FIG.2,

TBL.1, REF.44

JOURNAL NUMBER: Y0229AAZ ISSN NO: 0287-3796

UNIVERSAL DECIMAL CLASSIFICATION: 591.111.05+591.41

LANGUAGE: Japanese COUNTRY OF PUBLICATION: Japan

DOCUMENT TYPE: Journal

ARTICLE TYPE: Commentary

MEDIA TYPE: Printed Publication

10/3/4 (Item 1 from file: 266)

DIALOG(R)File 266:FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00363827

IDENTIFYING NO.: 1Z01SC00550-21 AGENCY CODE: CRISP
Immunologic Characterization of Malignant Lymphomas
PRINCIPAL INVESTIGATOR: JAFFE, ELAINE
ADDRESS: NCI SC, NIH
SPONSORING ORG.: DIVISION OF CLINICAL SCIENCES - NCI
FY : 2001

10/3/5 (Item 2 from file: 266)

DIALOG(R)File 266:FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00334537

IDENTIFYING NO.: 1Z01HG00077-03 AGENCY CODE: CRISP
TRANSCRIPTION TARGETING/CONDITIONAL EXPRESSION OF TRANSGENE--CANCER
IMMUNOTHERAP
PRINCIPAL INVESTIGATOR: XANTHOPOULOS, K G.
ADDRESS: NHGRI, NIH
SPONSORING ORG.: NATIONAL HUMAN GENOME RESEARCH INSTITUTE
FY : 2001

10/3/6 (Item 3 from file: 266)

DIALOG(R)File 266:FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00300108

IDENTIFYING NO.: 1Z01BC05598-12 AGENCY CODE: CRISP
Genetic Analysis of the Multidrug Resistance Phenotype in Tumor Cells
PRINCIPAL INVESTIGATOR: GOTTESMAN, MICHAEL M
ADDRESS: NCI BC, NIH
SPONSORING ORG.: DIVISION OF BASIC SCIENCES - NCI
FY : 2001

?-t-s10/k/1-6

>>>KWIC option is not available in file(s): 41, 77, 399

10/K/1 (Item 1 from file: 94)

DIALOG(R)File 94:(c)2002 Japan Science and Tech Corp(JST). All rts.
reserv.

...ABSTRACT: implicated in the signal transduction triggered by
granulocyte-macrophage colony-stimulating factor or erythropoietin in
hematopoietic cells. Here, we observed tyrosine phosphorylation of
c-Cbl in cells expressing epidermal growth factor...

...those of EGF receptor and Src protein, as well as in the signaling
pathways of **hematopoietic** cells. (author abst.)

...DESCRIPTORS: **neoplastic cell transformation**

...BROADER DESCRIPTORS: RNA virus; ...

...virus; ...

...animal virus;

10/K/2 (Item 2 from file: 94)

DIALOG(R)File 94:(c)2002 Japan Science and Tech Corp(JST). All rts.
reserv.

...DESCRIPTORS: **neoplastic cell transformation**

...BROADER DESCRIPTORS: RNA virus; ...

...virus; ...

...animal virus; ...

...virus genom...

...virus component...

...hematopoietic organ

10/K/3 (Item 3 from file: 94)
DIALOG(R)File 94:(c)2002 Japan Science and Tech Corp(JST). All rts.
reserv.

DESCRIPTORS: **hematopoietic stem cell**...

...**neoplastic cell transformation**

...BROADER DESCRIPTORS: **tumor virus**; ...

...virus; ...

...RNA virus; ...

...animal virus;

10/K/4 (Item 1 from file: 266)
DIALOG(R)File 266:Comp & dist by NTIS, Intl Copyright All Rights Res. All
rts. reserv.

...SUMMARY: females. We also have characterized blastic NK cell lymphomas, as a form of primitive **hematopoietic** malignancy frequently involving the skin with a high incidence of bone marrow involvement and...

...DESCRIPTORS: tissue; cytokine; lymphokine; immunogenetics; monoclonal antibody; neoplasm /cancer immunology; antitumor antibody; lymphoma; Burkitt's lymphoma; **neoplastic cell**; Epstein Barr **virus**; phenotype; chemokine

10/K/5 (Item 2 from file: 266)
DIALOG(R)File 266:Comp & dist by NTIS, Intl Copyright All Rights Res. All
rts. reserv.

...SUMMARY: EBP-alpha and C/EBP-epsilon, in cell proliferation and differentiation of hepatocytes, adipocytes and **hematopoietic** cells respectively. We study their the functional roles in vivo using homologous recombination for targeted...

... human cancers. This strategy is based on (i) highly efficient alphaviruses, e.g. Semliki Forest **Virus** (SFV) and (ii) hybrid Adenoviral/SFV chimeric vectors. SFV has several advantages over existing vectors...

DESCRIPTORS: laboratory mouse; transgenic animal; biological signal transduction; **hematopoietic stem cell**; cell differentiation; adipocyte; gene therapy; genetic manipulation; developmental genetics; genetic transcription; cytokine; liver cell; neoplasm /cancer immunotherapy; **neoplastic cell**; Adenoviridae; Alphavirus; transfection /expression vector; gene targeting; enhancer binding protein

10/K/6 (Item 3 from file: 266)
DIALOG(R)File 266:Comp & dist by NTIS, Intl Copyright All Rights Res. All

rts. reserv.

...SUMMARY: in the packaged DNA. This approach offers promise for transfer of P-gp into **hematopoietic** and other cells for gene therapy. We have also shown in a canine model...

...DESCRIPTORS: structure; gene therapy; genetic marker; gene expression; fungal genetics; cis platinum compound; adenocarcinoma; multidrug resistance; **neoplastic cell**; adenosinetriphosphatase; drug receptor; vaccinia **virus**; human genetic material tag; P glycoprotein; phenotype; enzyme activity; transfection /expression vector; green fluorescent protein
?